Welcome to Glythera Limited
Creating a new generation of biological therapeutics through advanced glycosylation technologies
Creating a new generation of biological therapeutics through advanced glycosylation technologies
PermaCarbTM
Maximise the in vivo benefits of your glycosylated therapeutics with a range of degredation resistant glycan analogues
Maximise the in vivo benefits of your glycosylated therapeutics with a range of degredation resistant glycan analogues
SNOB Reagents
The most simple and reliable reagents for direct detection, characterisation and visualisation of S-nitrosylated proteins
The most simple and reliable reagents for direct detection, characterisation and visualisation of S-nitrosylated proteins
News
Aug 10: Glythera and PATH sign collaboration agreement to evaluate new conjugation technology for pneumococcal vaccines. » Read More
May 09: Glythera advances key technologies in therapeutic protein engineering. » Read More
SNOB reagents can now be purchased from TOCRIS
Aug 10: Glythera and PATH sign collaboration agreement to evaluate new conjugation technology for pneumococcal vaccines. » Read More
May 09: Glythera advances key technologies in therapeutic protein engineering. » Read More
SNOB reagents can now be purchased from TOCRIS